These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 18991661)
21. Modes of drug delivery used to manage Parkinson's disease. Noble C Nurs Times; 2006 Aug 8-14; 102(32):30-2. PubMed ID: 16922099 [TBL] [Abstract][Full Text] [Related]
22. The comparative effects of medical therapies for Parkinson's disease. Horn S; Stern MB Neurology; 2004 Oct; 63(7 Suppl 2):S7-12. PubMed ID: 15477585 [No Abstract] [Full Text] [Related]
23. Current strategies in the treatment of Parkinson's disease and a personalized approach to management. Diaz NL; Waters CH Expert Rev Neurother; 2009 Dec; 9(12):1781-9. PubMed ID: 19951137 [TBL] [Abstract][Full Text] [Related]
24. New directions in the drug treatment of Parkinson's disease. Montastruc JL; Rascol O; Senard JM Drugs Aging; 1996 Sep; 9(3):169-84. PubMed ID: 8877311 [TBL] [Abstract][Full Text] [Related]
25. [Pharmacotherapy of Parkinson's disease: progress or regress?]. Pytka K; Zygmunt M; Filipek B Postepy Hig Med Dosw (Online); 2013 Jul; 67():700-8. PubMed ID: 24018435 [TBL] [Abstract][Full Text] [Related]
26. Drugs for Parkinson's disease. Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688 [TBL] [Abstract][Full Text] [Related]
27. Rationale for current therapies in Parkinson's disease. Romrell J; Fernandez HH; Okun MS Expert Opin Pharmacother; 2003 Oct; 4(10):1747-61. PubMed ID: 14521485 [TBL] [Abstract][Full Text] [Related]
29. Dopamine receptor agonists in the treatment of advanced Parkinson's disease. Stocchi F Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S54-7. PubMed ID: 20123558 [TBL] [Abstract][Full Text] [Related]
30. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Kalia LV; Brotchie JM; Fox SH Mov Disord; 2013 Feb; 28(2):131-44. PubMed ID: 23225267 [TBL] [Abstract][Full Text] [Related]
31. Advances in the treatment of Parkinson's disease. Singh N; Pillay V; Choonara YE Prog Neurobiol; 2007 Jan; 81(1):29-44. PubMed ID: 17258379 [TBL] [Abstract][Full Text] [Related]
33. [Drug therapy in Parkinson's disease]. van Hilten JJ; Roos RA Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151 [TBL] [Abstract][Full Text] [Related]
34. Designing prodrugs for the treatment of Parkinson's disease. Sozio P; Cerasa LS; Abbadessa A; Di Stefano A Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466 [TBL] [Abstract][Full Text] [Related]
35. Overview of Therapeutic Drugs and Methods for the Treatment of Parkinson's Disease. Schneider A; Sari AT; Alhaddad H; Sari Y CNS Neurol Disord Drug Targets; 2020; 19(3):195-206. PubMed ID: 32448109 [TBL] [Abstract][Full Text] [Related]
36. Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease. Faulkner MA Expert Opin Drug Saf; 2014 Aug; 13(8):1055-69. PubMed ID: 24962891 [TBL] [Abstract][Full Text] [Related]
37. The pharmacology of Parkinson's disease: basic aspects and recent advances. Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857 [TBL] [Abstract][Full Text] [Related]
38. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Deleu D; Northway MG; Hanssens Y Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145 [TBL] [Abstract][Full Text] [Related]
39. Future treatments for Parkinson's disease: surfing the PD pipeline. Hauser RA Int J Neurosci; 2011; 121 Suppl 2():53-62. PubMed ID: 22035030 [TBL] [Abstract][Full Text] [Related]
40. New drugs in the treatment of Parkinson's disease. An introduction. Bracco F Adv Neurol; 1996; 69():513-7. PubMed ID: 8615173 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]